A detailed history of Cowen And Company, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Cowen And Company, LLC holds 362 shares of EXEL stock, worth $12,050. This represents 0.0% of its overall portfolio holdings.

Number of Shares
362
Previous 29,000 98.75%
Holding current value
$12,050
Previous $651,000 98.62%
% of portfolio
0.0%
Previous 0.02%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$21.96 - $27.6 $7,949 - $9,991
362 New
362 $9,000
Q4 2023

Feb 12, 2024

BUY
$19.25 - $24.13 $1.78 Million - $2.24 Million
92,654 New
92,654 $2.22 Million
Q3 2021

Nov 12, 2021

SELL
$16.3 - $21.14 $314,948 - $408,467
-19,322 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$17.95 - $25.56 $346,829 - $493,870
19,322 New
19,322 $352,000
Q1 2021

May 04, 2021

SELL
$20.53 - $25.22 $98,153 - $120,576
-4,781 Closed
0 $0
Q4 2020

Feb 08, 2021

BUY
$18.39 - $24.8 $87,922 - $118,568
4,781 New
4,781 $96,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Cowen And Company, LLC Portfolio

Follow Cowen And Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cowen And Company, LLC with notifications on news.